Hola Sergio,
Nice to hear from you.
I have been around SI, but you are the one that had been hiding.<g>
Also hope everything remains well.
Regarding FOLD
As you know, their main products are orally administered small molecule drugs for the treatment of various human genetic diseases.
Those drugs have been called "chaperones" because they bind to the target protein increasing its stability and activity.
FOLD's primary focus seems to be on lysosomal storage disorders and diseases of neurodegeneration, which don't have a large market potential.
Its lead candidate is Amigal, which is in PIII for the treatment of patients with Fabry disease.
They also have AT2220 PI for Pompe disease and Plicera for the treatment of Gaucher disease.
Although I don't follow it too close, today it dipped below its near-term support at the $3.50 level, but was able to close on the black, on low volume in spite of some good sized down ticks in the last two minutes of trading.
(More than 2500 each in the one minute chart, with total volume for the day only 33,528.)
The insiders that had done some slight selling in May did some buying in June and August.
The ACTAY is $7.83
The important support seems to be at the $3 level, although in July last year it dipped below $2 <g>
It reportedly has around $2.40 in csh/shr and relatively small LTD, but negative CF around $12.6M and negative FCF around $25.88M
The first resistance is at the $5.50 level and then the $7.90 level, which is where they could start closing the Oct2009 DG.<g>
bigcharts.marketwatch.com
RAGL
Bernard
|
